Literature DB >> 23160422

Where, when, and in what form does sporadic Alzheimer's disease begin?

Heiko Braak1, Kelly Del Tredici.   

Abstract

PURPOSE OF REVIEW: Intraneuronal lesions consisting of abnormal tau protein are seen to develop from the beginning until the end-phase of the pathological process underlying Alzheimer's disease. This review highlights the earliest phase of this process. RECENT
FINDINGS: Development of abnormal tau frequently begins during childhood or puberty in nuclei of the lower brainstem sending diffuse projections to the cerebral cortex. Nonfibrillar abnormal tau material first occurs in the proximal axon of projection neurons in the locus coeruleus. Subsequently, a similar material (pretangle material) fills the somatodendritic compartment. In contrast with the pretangle material in cell bodies and dendrites, the nonfibrillar material in the axon normally does not convert into stable fibrillary inclusions.
SUMMARY: Projection neurons (not only those of the locus coeruleus) are sturdy and can survive for a lifetime despite the existence of Alzheimer-related abnormal tau. Currently, little understood mechanisms most probably exist that enable neurons to fulfill their general functions even when severe tau pathology is present. The proclivity of predisposed neuronal types to develop abnormal tau may be intrinsic to the human brain. However, the tempo of disease progression reveals considerable individual differences, thereby offering opportunities to study conditions that may modify disease progression.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23160422     DOI: 10.1097/WCO.0b013e32835a3432

Source DB:  PubMed          Journal:  Curr Opin Neurol        ISSN: 1350-7540            Impact factor:   5.710


  77 in total

1.  Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease.

Authors:  Andrei G Vlassenko; Lena McCue; Mateusz S Jasielec; Yi Su; Brian A Gordon; Chengjie Xiong; David M Holtzman; Tammie L S Benzinger; John C Morris; Anne M Fagan
Journal:  Ann Neurol       Date:  2016-07-25       Impact factor: 10.422

2.  Dual-tagged amyloid-β precursor protein reveals distinct transport pathways of its N- and C-terminal fragments.

Authors:  Christine Villegas; Virgil Muresan; Zoia Ladescu Muresan
Journal:  Hum Mol Genet       Date:  2013-11-07       Impact factor: 6.150

3.  HS3ST2 expression is critical for the abnormal phosphorylation of tau in Alzheimer's disease-related tau pathology.

Authors:  Julia Elisa Sepulveda-Diaz; Seyedeh Maryam Alavi Naini; Minh Bao Huynh; Mohand Ouidir Ouidja; Constantin Yanicostas; Sandrine Chantepie; Joao Villares; Foudil Lamari; Estelle Jospin; Toin H van Kuppevelt; Ayikoe Guy Mensah-Nyagan; Rita Raisman-Vozari; Nadia Soussi-Yanicostas; Dulce Papy-Garcia
Journal:  Brain       Date:  2015-04-04       Impact factor: 13.501

4.  Stages of pTDP-43 pathology in amyotrophic lateral sclerosis.

Authors:  Johannes Brettschneider; Kelly Del Tredici; Jon B Toledo; John L Robinson; David J Irwin; Murray Grossman; EunRan Suh; Vivianna M Van Deerlin; Elisabeth M Wood; Young Baek; Linda Kwong; Edward B Lee; Lauren Elman; Leo McCluskey; Lubin Fang; Simone Feldengut; Albert C Ludolph; Virginia M-Y Lee; Heiko Braak; John Q Trojanowski
Journal:  Ann Neurol       Date:  2013-06-19       Impact factor: 10.422

Review 5.  Imaging the evolution and pathophysiology of Alzheimer disease.

Authors:  William Jagust
Journal:  Nat Rev Neurosci       Date:  2018-11       Impact factor: 34.870

6.  Pulse pressure in relation to tau-mediated neurodegeneration, cerebral amyloidosis, and progression to dementia in very old adults.

Authors:  Daniel A Nation; Emily C Edmonds; Katherine J Bangen; Lisa Delano-Wood; Blake K Scanlon; S Duke Han; Steven D Edland; David P Salmon; Douglas R Galasko; Mark W Bondi
Journal:  JAMA Neurol       Date:  2015-05       Impact factor: 18.302

Review 7.  Clinical trials and late-stage drug development for Alzheimer's disease: an appraisal from 1984 to 2014.

Authors:  L S Schneider; F Mangialasche; N Andreasen; H Feldman; E Giacobini; R Jones; V Mantua; P Mecocci; L Pani; B Winblad; M Kivipelto
Journal:  J Intern Med       Date:  2014-03       Impact factor: 8.989

Review 8.  The dendritic hypothesis for Alzheimer's disease pathophysiology.

Authors:  J Nicholas Cochran; Alicia M Hall; Erik D Roberson
Journal:  Brain Res Bull       Date:  2013-12-12       Impact factor: 4.077

9.  Complex noradrenergic dysfunction in Alzheimer's disease: Low norepinephrine input is not always to blame.

Authors:  Mary Gannon; Qin Wang
Journal:  Brain Res       Date:  2018-01-04       Impact factor: 3.252

Review 10.  Amyotrophic lateral sclerosis--a model of corticofugal axonal spread.

Authors:  Heiko Braak; Johannes Brettschneider; Albert C Ludolph; Virginia M Lee; John Q Trojanowski; Kelly Del Tredici
Journal:  Nat Rev Neurol       Date:  2013-11-12       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.